Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the United Kingdom at the University College London. This multinational clinical trial sponsored by Immunophotonics will assess the safety and efficacy of its lead asset, IP-001, and is currently enrolling patients for treatment of colorectal cancer,...
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th Annual Immuno-Oncology Innovation Forum, June 2, and the ASCO (American Society of Clinical Oncology) annual meeting, June 2 – 6. They will be connecting with investors and clinical experts to discuss how Immunophotonics continues to...
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of patients based on the company’s investigational new drug (IND) application. This extends the company’s INJECTABL-1 trial to the treatment of metastatic colorectal cancer, lung cancer, and sarcoma patients in the USA. Read more (Official Press...
Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development Theresa Visarius will present initial clinical and translational data on the use of IP-001 in solid tumor indications on April 24th in the Clinical Stage Development Companies session.
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Booth 10 at the European Conference on Interventional Oncology (ECIO 2023) in Stockholm, Sweden, on April 16 – 19. They are looking forward to connecting with clinical experts and learning from their experiences, as well as discussing how Immunophotonics continues...
Immunophotonics is excited to announce that its composition-of-matter patent has been granted by the Indian Patent Office (ISA/IPEA). With this issuance, India has joined over 50 countries in granting Immunophotonics patent protection to the composition of matter underlying a range of polymers that encompasses the company’s lead drug candidate, IP-001. Crucially, this latest patent allowance...
Lu Alleruzzo, CEO & Co-Founder; and Tomas Hode, PhD, Co-Founder, CIO, & President were delighted to receive an invitation to attend the AngioDynamic International Life Symposium taking place in Rome, Italy, March 30 – April 1. They will be connecting with clinical experts and industry partners from around the world and learning about the latest...
Immunophotonics, Inc. is grateful to NCI (the National Cancer Institute of NIH) and its SBIR Investor Initiatives Team for sponsoring Immunophotonics to present its technology and novel approach to cancer treatment at the BIO CEO & Investor Conference taking place February 6 – 9, 2023 at the New York Marriot Marquis in New York City. ...
Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety and efficacy of its lead asset, IP-001, in multiple solid tumor indications. This multinational clinical trial, denominated alternately as IP-IIO or INJECTABLE-1, is sponsored by Immunophotonics and will be enrolling patients for treatment of colorectal...
Tomas Hode, PhD, Co-Founder, CIO, and President at @Immunophotonics, Inc. will be attending the Society of Interventional Oncology (SIO) 2023 annual scientific meeting January 19 – 23, in Washington, DC. Tomas will be connecting with interventional oncology professionals from around the world and learning about the latest developments in improving cancer care alongside medical, surgical...
